Increasing the class of foundational medication for heart failure is associated with improved prognosis in hospitalized patients with heart failure with reduced or mildly reduced ejection fraction

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Daichi Maeda

Juntendo University Graduate School of Medicine, Tokyo (Japan)

4 More presentations in this session

Presentation thumbnail

Heart failure therapy in new onset heart failure versus chronic heart failure: an analysis of 90,383 patients from the Swedish Heart Failure Registry (SwedeHF)

Ms A. Shahim (Stockholm, SE)

Abstract Slides

Presentation thumbnail

Ultra-fast remote up-titration of heart failure treatment: a safe, efficient and feasible protocol

Doctor M. Massot (Toulouse, FR)

Abstract Slides

Presentation thumbnail

Effects of sodium glucose cotransporter 2 inhibitors on the risk of hyperkalemia in patients on mineralocorticoid receptor antagonist: a systematic review and meta-analysis

Doctor R. Cordovez (Cebu City, PH)

Abstract Slides

Presentation thumbnail

Effect of diuretic down-titration on pulmonary congestion assessed by lung ultrasound when introducing sodium-glucose cotransporter 2 inhibitors

Doctor M. Domingo (Badalona, ES)

Abstract Slides

Access the full session

Session thumbnail

Chronic heart failure treatment

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Congress Presentation

Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion

Congress Presentation

The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources